Cargando…

Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure

Liver failure is a severe clinical syndrome with high mortality. 5-Hydroxytryptamine 3 receptor antagonists (5-HT3RAs) can reduce liver damage in animal models. We investigated whether 5-HT3RAs may improve the prognosis of liver failure. We analyzed the 28 and 90 days mortality of liver failure pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yuting, Sun, Jingkang, Fan, Xiude, Wang, Xiaoyun, Zeng, Lu, Zhang, Xiaoge, Zhang, Kun, Li, Na, Han, Qunying, Liu, Zhengwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100675/
https://www.ncbi.nlm.nih.gov/pubmed/33967787
http://dx.doi.org/10.3389/fphar.2021.648736
_version_ 1783688839318994944
author Chen, Yuting
Sun, Jingkang
Fan, Xiude
Wang, Xiaoyun
Zeng, Lu
Zhang, Xiaoge
Zhang, Kun
Li, Na
Han, Qunying
Liu, Zhengwen
author_facet Chen, Yuting
Sun, Jingkang
Fan, Xiude
Wang, Xiaoyun
Zeng, Lu
Zhang, Xiaoge
Zhang, Kun
Li, Na
Han, Qunying
Liu, Zhengwen
author_sort Chen, Yuting
collection PubMed
description Liver failure is a severe clinical syndrome with high mortality. 5-Hydroxytryptamine 3 receptor antagonists (5-HT3RAs) can reduce liver damage in animal models. We investigated whether 5-HT3RAs may improve the prognosis of liver failure. We analyzed the 28 and 90 days mortality of liver failure patients in relation to the use of 5-HT3RAs using data from a tertiary hospital in northwest China. According to the use of 5-HT3RAs, 419 patients with liver failure (46 acute, 93 sub-acute, 44 chronic, 236 acute on chronic) were divided into 5-HT3RA group (n = 105) and control group (n = 314). 5-HT3RAs were associated with decreased 28 days (HR 0.18, 95% CI 0.10-0.34, p < 0.001) and 90 days (HR 0.21, 95% CI 0.13-0.33, p < 0.001) mortality. After propensity score matching (PSM) (n = 67 in each group), 5-HT3RAs were still significantly associated with reduced 28 days (HR 0.10, 95%CI 0.04-0.26, p < 0.001) and 90 days (HR 0.16, 95%CI 0.08-0.31, p < 0.001) mortality. 5-HT3RA group patients had significantly higher 28 and 90 days survivals than controls both before and after PSM (all p < 0.001). This study shows that 5-HT3RAs are associated with increased survival of liver failure patients and thus may be used to treat liver failure if the findings are confirmed by additional studies.
format Online
Article
Text
id pubmed-8100675
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81006752021-05-07 Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure Chen, Yuting Sun, Jingkang Fan, Xiude Wang, Xiaoyun Zeng, Lu Zhang, Xiaoge Zhang, Kun Li, Na Han, Qunying Liu, Zhengwen Front Pharmacol Pharmacology Liver failure is a severe clinical syndrome with high mortality. 5-Hydroxytryptamine 3 receptor antagonists (5-HT3RAs) can reduce liver damage in animal models. We investigated whether 5-HT3RAs may improve the prognosis of liver failure. We analyzed the 28 and 90 days mortality of liver failure patients in relation to the use of 5-HT3RAs using data from a tertiary hospital in northwest China. According to the use of 5-HT3RAs, 419 patients with liver failure (46 acute, 93 sub-acute, 44 chronic, 236 acute on chronic) were divided into 5-HT3RA group (n = 105) and control group (n = 314). 5-HT3RAs were associated with decreased 28 days (HR 0.18, 95% CI 0.10-0.34, p < 0.001) and 90 days (HR 0.21, 95% CI 0.13-0.33, p < 0.001) mortality. After propensity score matching (PSM) (n = 67 in each group), 5-HT3RAs were still significantly associated with reduced 28 days (HR 0.10, 95%CI 0.04-0.26, p < 0.001) and 90 days (HR 0.16, 95%CI 0.08-0.31, p < 0.001) mortality. 5-HT3RA group patients had significantly higher 28 and 90 days survivals than controls both before and after PSM (all p < 0.001). This study shows that 5-HT3RAs are associated with increased survival of liver failure patients and thus may be used to treat liver failure if the findings are confirmed by additional studies. Frontiers Media S.A. 2021-04-22 /pmc/articles/PMC8100675/ /pubmed/33967787 http://dx.doi.org/10.3389/fphar.2021.648736 Text en Copyright © 2021 Chen, Sun, Fan, Wang, Zeng, Zhang, Zhang, Li, Han and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Chen, Yuting
Sun, Jingkang
Fan, Xiude
Wang, Xiaoyun
Zeng, Lu
Zhang, Xiaoge
Zhang, Kun
Li, Na
Han, Qunying
Liu, Zhengwen
Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure
title Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure
title_full Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure
title_fullStr Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure
title_full_unstemmed Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure
title_short Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure
title_sort association of 5-hydroxytryptamine 3 receptor antagonists with the prognosis of liver failure
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100675/
https://www.ncbi.nlm.nih.gov/pubmed/33967787
http://dx.doi.org/10.3389/fphar.2021.648736
work_keys_str_mv AT chenyuting associationof5hydroxytryptamine3receptorantagonistswiththeprognosisofliverfailure
AT sunjingkang associationof5hydroxytryptamine3receptorantagonistswiththeprognosisofliverfailure
AT fanxiude associationof5hydroxytryptamine3receptorantagonistswiththeprognosisofliverfailure
AT wangxiaoyun associationof5hydroxytryptamine3receptorantagonistswiththeprognosisofliverfailure
AT zenglu associationof5hydroxytryptamine3receptorantagonistswiththeprognosisofliverfailure
AT zhangxiaoge associationof5hydroxytryptamine3receptorantagonistswiththeprognosisofliverfailure
AT zhangkun associationof5hydroxytryptamine3receptorantagonistswiththeprognosisofliverfailure
AT lina associationof5hydroxytryptamine3receptorantagonistswiththeprognosisofliverfailure
AT hanqunying associationof5hydroxytryptamine3receptorantagonistswiththeprognosisofliverfailure
AT liuzhengwen associationof5hydroxytryptamine3receptorantagonistswiththeprognosisofliverfailure